CA2778961C - Compounds and methods for the treatment of inflammatory diseases of the cns - Google Patents

Compounds and methods for the treatment of inflammatory diseases of the cns Download PDF

Info

Publication number
CA2778961C
CA2778961C CA2778961A CA2778961A CA2778961C CA 2778961 C CA2778961 C CA 2778961C CA 2778961 A CA2778961 A CA 2778961A CA 2778961 A CA2778961 A CA 2778961A CA 2778961 C CA2778961 C CA 2778961C
Authority
CA
Canada
Prior art keywords
seq
oligonucleotide
cells
carrier
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2778961A
Other languages
English (en)
French (fr)
Other versions
CA2778961A1 (en
Inventor
Lisa Charlotta Bandholtz
Alexander Gielen
Arezou Zargari
Oliver Von Stein
Lars-Goran Axelsson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Index Pharmaceuticals AB
Original Assignee
Index Pharmaceuticals AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Index Pharmaceuticals AB filed Critical Index Pharmaceuticals AB
Publication of CA2778961A1 publication Critical patent/CA2778961A1/en
Application granted granted Critical
Publication of CA2778961C publication Critical patent/CA2778961C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/17—Immunomodulatory nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/313—Phosphorodithioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CA2778961A 2008-11-04 2009-11-04 Compounds and methods for the treatment of inflammatory diseases of the cns Active CA2778961C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US11128708P 2008-11-04 2008-11-04
US61/111,287 2008-11-04
SE0802339 2008-11-04
SE0802339-2 2008-11-04
PCT/SE2009/051247 WO2010053435A2 (en) 2008-11-04 2009-11-04 Compounds and methods for the treatment of inflammatory diseases of the cns

Publications (2)

Publication Number Publication Date
CA2778961A1 CA2778961A1 (en) 2010-05-14
CA2778961C true CA2778961C (en) 2019-06-18

Family

ID=42153438

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2778961A Active CA2778961C (en) 2008-11-04 2009-11-04 Compounds and methods for the treatment of inflammatory diseases of the cns

Country Status (8)

Country Link
US (3) US8637479B2 (enExample)
EP (1) EP2350283B1 (enExample)
JP (1) JP5746038B2 (enExample)
AU (1) AU2009311753B2 (enExample)
CA (1) CA2778961C (enExample)
DK (1) DK2350283T3 (enExample)
ES (1) ES2560782T3 (enExample)
WO (1) WO2010053435A2 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2464731T3 (es) 2008-11-04 2014-06-03 Index Pharmaceuticals Ab Compuestos y procedimientos para reducir el reclutamiento y/o migración de células polimorfonucleares
EP2468866A1 (en) * 2010-12-21 2012-06-27 Index Pharmaceuticals AB Biologically active oligonucleotides capable of modulating the immune system
WO2012084991A1 (en) * 2010-12-21 2012-06-28 Index Pharmaceuticals Ab Biologically active oligonucleotides capable of modulating the immune system ii
EP2596806A1 (en) 2011-11-25 2013-05-29 Index Pharmaceuticals AB Method for prevention of colectomy
US11672757B2 (en) * 2017-06-28 2023-06-13 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Hot melt extrusion for pharmaceutical vaginal film products

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR040996A1 (es) * 2002-08-19 2005-04-27 Coley Pharm Group Inc Acidos nucleicos inmunoestimuladores
AU2004255470B2 (en) * 2003-07-10 2010-08-19 Cytos Biotechnology Ag Packaged virus-like particles
EP1819364A4 (en) * 2004-12-08 2010-12-29 3M Innovative Properties Co COMPOSITIONS, IMMUNOMODULATORY COMBINATIONS AND ASSOCIATED METHODS
WO2006065751A2 (en) 2004-12-13 2006-06-22 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Cpg oligonucleotide prodrugs, compositions thereof and associated therapeutic methods
SI2380584T1 (sl) * 2005-07-01 2014-04-30 Index Pharmaceuticals Ab Imunostimulatorni postopek
PT2179737E (pt) * 2005-07-01 2013-12-05 Index Pharmaceuticals Ab Método para modular a capacidade de resposta aos esteróides
WO2007030581A2 (en) * 2005-09-09 2007-03-15 Oregon Health & Science University Neuroprotectants
AU2006306805A1 (en) 2005-10-28 2007-05-03 Index Pharmaceuticals Ab Composition and method for the prevention, treatment and/or alleviation of an inflammatory disease
WO2007095316A2 (en) 2006-02-15 2007-08-23 Coley Pharmaceutical Gmbh Compositions and methods for oligonucleotide formulations
EP1894941A1 (en) * 2006-09-01 2008-03-05 Institut Pasteur Treatment of cervical carcinoma with a recombinant adenylate cyclase carrying HPV antigens
US8309529B2 (en) * 2007-05-04 2012-11-13 Index Pharmaceuticals Ab Tumour growth inhibitory compounds and methods of their use
EP2155889A4 (en) * 2007-05-25 2010-06-16 Centocor Ortho Biotech Inc TOLL RECEPTOR 3 MODULATORS AND USES THEREOF
EP2207555B1 (en) 2007-10-05 2013-07-24 InDex Pharmaceuticals AB Oligonucleotides for the treatment or alleviation of edema
US20110182880A1 (en) 2008-06-18 2011-07-28 Oliver Von Stein Combination Therapies Against Cancer
ES2464731T3 (es) * 2008-11-04 2014-06-03 Index Pharmaceuticals Ab Compuestos y procedimientos para reducir el reclutamiento y/o migración de células polimorfonucleares

Also Published As

Publication number Publication date
AU2009311753B2 (en) 2015-01-15
EP2350283A2 (en) 2011-08-03
JP5746038B2 (ja) 2015-07-08
AU2009311753A1 (en) 2010-05-14
WO2010053435A3 (en) 2010-07-08
EP2350283B1 (en) 2015-11-04
WO2010053435A2 (en) 2010-05-14
CA2778961A1 (en) 2010-05-14
US20180230463A1 (en) 2018-08-16
US8637479B2 (en) 2014-01-28
US20110293702A1 (en) 2011-12-01
US20140128456A1 (en) 2014-05-08
DK2350283T3 (en) 2016-02-01
JP2012507308A (ja) 2012-03-29
ES2560782T3 (es) 2016-02-22
EP2350283A4 (en) 2013-02-13

Similar Documents

Publication Publication Date Title
US20180230463A1 (en) Compounds and Methods for the Treatment of Inflammatory Diseases of the CNS
US11883409B2 (en) Protection of cells from degeneration and treatment of geographic atrophy
IL164664A (en) Use of polynucleotide sequences in the manufacture of a medicament for stimulating an immune response
JPWO2016079899A1 (ja) 異なる核酸アジュバントの組み合わせによる、新規Ｔｈ１誘導性アジュバントおよびその用途
US20120177632A1 (en) Methods of optimizing disease treatment
JP7758356B2 (ja) 敗血症および高サイトカイン血症の治療薬
US20180289692A1 (en) Tlr modulators and methods of use
RS61274B1 (sr) Jednolančani oligonukleotidi za upotrebu u medicinskom lečenju poremećaja kože
Sun et al. Knockdown of IFIT3 ameliorates multiple sclerosis via selectively regulating M1 polarization of microglia in an experimental autoimmune encephalomyelitis model
WO2016009430A1 (en) Reduction of aging-induced type i interferon signaling at the brain's choroid plexus or within the cns for treatment of disease or injury of the cns
AU2007237059B2 (en) Antisense oligonucleotides against acetylcholinesterase for treating inflammatory diseases
US20110104138A1 (en) Use of the innate immunity gene oasl for preventing or treating infection with negative strand rna viruses
EP2658550A1 (en) Agonists of toll like receptor for treating cardiovasuclar disease and obesity
CN101701218B (zh) 一种抑制Th1和Th17分化的免疫调节性寡聚脱氧核苷酸及应用
Zhang et al. Manf enhances the pyroptosis inhibition of bone marrow-derived mesenchymal stem cells to relieve cerebral infarction Injury
CN115684594A (zh) Trem-2在制备多发性硬化症的治疗药物和/或诊断试剂中的应用
US20170136089A1 (en) Compositions and methods of regulating bone resorption
Becker et al. Emerging treatment strategies and potential therapeutic targets in primary Sjogren's syndrome
JP7267922B2 (ja) 新規製剤
EP2796563A1 (en) Optimized degenerative muscle disease diagnostics and treatments
CN108096579A (zh) 以c-Rel基因为靶点在制备治疗类风湿性关节炎的药物中的应用
CN111939246A (zh) E3泛素连接酶Nedd4l在制备抗感染药物中的应用
DeVasure et al. An association between MMP-9 and impaired T cell migration in ethanol-fed BALB/c mice infected with respiratory syncytial virus-2A.
CN113789328A (zh) lncRNA及其在免疫调控及免疫相关疾病诊治中的应用
Limborska et al. Semax, an analog of ACTH, regulates expression of immune response genes during ischemic brain injury in rats.

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20141104

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251020

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251217

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-H100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE AND LATE FEE NOT PAID BY DEADLINE OF NOTICE

Effective date: 20260202

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260203

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-6-6-H10-H13-H100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE AND LATE FEE NOT PAID BY DEADLINE OF NOTICE

Effective date: 20260615

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260713